Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN CARLOS, Calif., Oct. 08, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and...
-
SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of eosinophil and...
-
SAN CARLOS, Calif., July 24, 2018 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various...
-
SAN CARLOS, Calif., July 19, 2018 (GLOBE NEWSWIRE) -- Allakos Inc., (Nasdaq:ALLK), a clinical stage biotechnology company focused on the development of antibodies for the treatment of various...
-
-- Phase 1 data demonstrate AK002 rapidly depletes blood eosinophils after a single dose -- -- AK002 may provide an important new option in treating chronic allergic and inflammatory diseases such as...
-
Proceeds will support advancement of AK002 in five disease areas Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease SAN CARLOS,...
-
Board of Directors appoints Robert Alexander as CEO and Adam Tomasi as COO & CFO Allakos plans to initiate a broad, multi-indication clinical program with AK002 in 2017 SAN CARLOS, Calif., Aug. ...